300 related articles for article (PubMed ID: 25807289)
1. Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques.
Evgin L; Acuna SA; Tanese de Souza C; Marguerie M; Lemay CG; Ilkow CS; Findlay CS; Falls T; Parato KA; Hanwell D; Goldstein A; Lopez R; Lafrance S; Breitbach CJ; Kirn D; Atkins H; Auer RC; Thurman JM; Stahl GL; Lambris JD; Bell JC; McCart JA
Mol Ther; 2015 Jun; 23(6):1066-1076. PubMed ID: 25807289
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans.
Kim MK; Breitbach CJ; Moon A; Heo J; Lee YK; Cho M; Lee JW; Kim SG; Kang DH; Bell JC; Park BH; Kirn DH; Hwang TH
Sci Transl Med; 2013 May; 5(185):185ra63. PubMed ID: 23677592
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic and immunologic cancer therapy with GM-CSF-armed vaccinia virus of Tian Tan strain Guang9.
Deng L; Fan J; Guo M; Huang B
Cancer Lett; 2016 Mar; 372(2):251-7. PubMed ID: 26803055
[TBL] [Abstract][Full Text] [Related]
4. Generation of novel oncolytic vaccinia virus with improved intravenous efficacy through protection against complement-mediated lysis and evasion of neutralization by vaccinia virus-specific antibodies.
Lee N; Jeon YH; Yoo J; Shin SK; Lee S; Park MJ; Jung BJ; Hong YK; Lee DS; Oh K
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36717184
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic efficacy of thymidine kinase-deleted vaccinia virus strain Guang9.
Deng L; Fan J; Ding Y; Zhang J; Zhou B; Zhang Y; Huang B
Oncotarget; 2017 Jun; 8(25):40533-40543. PubMed ID: 28465492
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients.
Cripe TP; Ngo MC; Geller JI; Louis CU; Currier MA; Racadio JM; Towbin AJ; Rooney CM; Pelusio A; Moon A; Hwang TH; Burke JM; Bell JC; Kirn DH; Breitbach CJ
Mol Ther; 2015 Mar; 23(3):602-8. PubMed ID: 25531693
[TBL] [Abstract][Full Text] [Related]
7. Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers.
Draganov DD; Santidrian AF; Minev I; Nguyen D; Kilinc MO; Petrov I; Vyalkova A; Lander E; Berman M; Minev B; Szalay AA
J Transl Med; 2019 Mar; 17(1):100. PubMed ID: 30917829
[TBL] [Abstract][Full Text] [Related]
8. Transient Inhibition of PI3Kδ Enhances the Therapeutic Effect of Intravenous Delivery of Oncolytic Vaccinia Virus.
Ferguson MS; Chard Dunmall LS; Gangeswaran R; Marelli G; Tysome JR; Burns E; Whitehead MA; Aksoy E; Alusi G; Hiley C; Ahmed J; Vanhaesebroeck B; Lemoine NR; Wang Y
Mol Ther; 2020 May; 28(5):1263-1275. PubMed ID: 32145202
[TBL] [Abstract][Full Text] [Related]
9. First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activity.
Zeh HJ; Downs-Canner S; McCart JA; Guo ZS; Rao UN; Ramalingam L; Thorne SH; Jones HL; Kalinski P; Wieckowski E; O'Malley ME; Daneshmand M; Hu K; Bell JC; Hwang TH; Moon A; Breitbach CJ; Kirn DH; Bartlett DL
Mol Ther; 2015 Jan; 23(1):202-14. PubMed ID: 25292189
[TBL] [Abstract][Full Text] [Related]
10. Inhibitors of C5 complement enhance vaccinia virus oncolysis.
Magge D; Guo ZS; O'Malley ME; Francis L; Ravindranathan R; Bartlett DL
Cancer Gene Ther; 2013 Jun; 20(6):342-50. PubMed ID: 23661042
[TBL] [Abstract][Full Text] [Related]
11. Engineering oncolytic vaccinia virus with functional peptides through mild and universal strategy.
Huang LL; Li X; Liu K; Zou B; Xie HY
Anal Bioanal Chem; 2019 Feb; 411(4):925-933. PubMed ID: 30523361
[TBL] [Abstract][Full Text] [Related]
12. A cancer-favoring oncolytic vaccinia virus shows enhanced suppression of stem-cell like colon cancer.
Yoo SY; Bang SY; Jeong SN; Kang DH; Heo J
Oncotarget; 2016 Mar; 7(13):16479-89. PubMed ID: 26918725
[TBL] [Abstract][Full Text] [Related]
13. Synergistic interaction between oncolytic viruses augments tumor killing.
Le Boeuf F; Diallo JS; McCart JA; Thorne S; Falls T; Stanford M; Kanji F; Auer R; Brown CW; Lichty BD; Parato K; Atkins H; Kirn D; Bell JC
Mol Ther; 2010 May; 18(5):888-95. PubMed ID: 20234341
[TBL] [Abstract][Full Text] [Related]
14. The combination of immunosuppression and carrier cells significantly enhances the efficacy of oncolytic poxvirus in the pre-immunized host.
Guo ZS; Parimi V; O'Malley ME; Thirunavukarasu P; Sathaiah M; Austin F; Bartlett DL
Gene Ther; 2010 Dec; 17(12):1465-75. PubMed ID: 20703311
[TBL] [Abstract][Full Text] [Related]
15. Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer.
Park SH; Breitbach CJ; Lee J; Park JO; Lim HY; Kang WK; Moon A; Mun JH; Sommermann EM; Maruri Avidal L; Patt R; Pelusio A; Burke J; Hwang TH; Kirn D; Park YS
Mol Ther; 2015 Sep; 23(9):1532-40. PubMed ID: 26073886
[TBL] [Abstract][Full Text] [Related]
16. Enhancing poxvirus oncolytic effects through increased spread and immune evasion.
Kirn DH; Wang Y; Liang W; Contag CH; Thorne SH
Cancer Res; 2008 Apr; 68(7):2071-5. PubMed ID: 18381410
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic vaccinia virus GLV-1h68 exhibits profound antitumoral activities in cell lines originating from neuroendocrine neoplasms.
Kloker LD; Berchtold S; Smirnow I; Beil J; Krieg A; Sipos B; Lauer UM
BMC Cancer; 2020 Jul; 20(1):628. PubMed ID: 32631270
[TBL] [Abstract][Full Text] [Related]
18. Activity of vaccinia virus-neutralizing antibody in the sera of smallpox vaccinees.
Viner KM; Isaacs SN
Microbes Infect; 2005 Apr; 7(4):579-83. PubMed ID: 15848274
[TBL] [Abstract][Full Text] [Related]
19. A novel high-throughput vaccinia virus neutralization assay and preexisting immunity in populations from different geographic regions in China.
Liu Q; Huang W; Nie J; Zhu R; Gao D; Song A; Meng S; Xu X; Wang Y
PLoS One; 2012; 7(3):e33392. PubMed ID: 22438922
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination.
Roy DG; Geoffroy K; Marguerie M; Khan ST; Martin NT; Kmiecik J; Bobbala D; Aitken AS; de Souza CT; Stephenson KB; Lichty BD; Auer RC; Stojdl DF; Bell JC; Bourgeois-Daigneault MC
Nat Commun; 2021 May; 12(1):2626. PubMed ID: 33976179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
